Ullrich H, Kadar J, Waxenberger Y, Hohe R, Saueressig C, Heyder M, et al. Therapeutic thrombocytapheresis in patients with myeloproliferative diseases with the cell separators Fresenius AS 104 and Cobe Spectra: Biocompatibility and safety.
8/04/2019· Plateletpheresis (or thrombocytapheresis): Process of removing platelets using an automated machine Currently available instrumentations for plateletpheresis procedures are COBE Spectra and Trima Accel from Terumo and Fenwal Amicus from Fresenius Kabi
4/04/2018· Introduction. Spectra Optia ® (SPO, Terumo BCT, Lakewood, CO, USA), a new and refined apheresis system that replaced the Cobe Spectra (Cobe; Terumo BCT, Lakewood, CO, USA), is based on the established Trima and Cobe technologies. SPO is now widely used in routine clinical practice as it enables the operators to perform a variety of procedures such as
Thrombocytapheresis procedures were reproducible and Spectra Optia system successfully adjusted settings to each procedure conditions. Thrombocytapheresis seems to be a viable and safe option even
Spectra Optia had a significantly higher plasma removal efficiency versus COBE Spectra (84% vs.75%, P?<?.05). No serious adverse events were observed. Conclusion: Apheresis procedures on
Over the years a number of apheresis platforms have been utilized, but as one of the oldest and most widely used systems, the COBE Spectra, has ceased to be used therapeutically and at blood centers for donations there is an active search to find suitable systems that will replace it and have the versatility to perform as many procedures as
The Spectra Optia apheresis system has only recently been approved by the Food and Drug Administration (FDA) for therapeutic white blood cell (WBC) depletions and is
Spectra Optia apheresis system: experience with secondary plasma devices. Article (PDF Available) · May 2017 with 493 Reads How we measure 'reads' A 'read' is counted each time someone views a
Leukopak 101: A Brief Review of Apheresis. Lily C. Trajman, Ph.D. [email protected] Introduction. Apheresis refers to the process by which blood is removed from a patient and separated into its constituent parts, allowing the removal of one specific component from the blood while the remainder is returned to the patient.
Page 1 of 47 FDA Executive Summary Prepared for the February 26, 2016 Meeting of the Gastroenterology-Urology Devices Panel Classification of Centrifuge-Type Therapeutic
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text.
of four types of apheresis machines; Trima, Amicus, MCS+ and Cobe Spectra in terms of their platelet activation status and, in addition, to propose the best method to achieve the good quality of platelet concentrates. Methodology: The study included 120 samples of platelet concentrates supplied by the National Blood Centre, Kuala Lumpur, Malaysia.
Apheresis (ἀφαίρεσις (aphairesis, "a taking away")) is a medical technology in which the blood of a person is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation. It is thus an extracorporeal therapy.. The apheresis machine was invented by American medical technologist Herb Cullis in 1972.
APCs produced with the Amicus device were stored in 65% T-Sol ® (PAS II, Baxter) and 35% autologous plasma according to the manufacturer's instructions, whereas PLTs derived from the Trima and Spectra devices were stored in 100% autologous plasma. APCs were stored at 22 ± 2 °C for a maximum of 5 days on a flat-bed shaker with constant
Currently used systems for platelet apheresis include COBE ® Spectra, Terumo ® Trima and Fenwal Amicus ®. COBE ® spectra and Spectra Optia are currently the only one approved for therapeutic plateletpheresis,. Single needle access procedures are equivalent in efficacy and quality to dual needle plateletpheresis protocols . Total of 1.5-2
Fifty-two Apheresis Units have also indicated, by filling in the questionnaires, the diagnosis list (Table 10 panel A).Only 40.5% out of the total therapeutic apheresis procedures has been applied to the most common diseases where such a treatment is a traditional therapeutic tool, including myasthenia gravis, Guillain Barré syndrome, cryoglobulinemia, thrombotic thrombocytopenic purpura.
The establishment of in‐house neurology driven therapeutic plasma exchange infrastructure in a resource‐limited public hospital in Malaysia: Adopting and integrating evidenced‐based health care technology through time
The Fresenius AS204 is ready for better-quality combined platelet collection, and RBC-PC collection with Cobe Spectra is under evaluation along with the leucocyte reduction system that apparently brings leucocyte contamination down to 0.35 × 10 5. This interest in thrombocytapheresis is also the result of the challenge that thrombopoietin phase I and II trials have promoted.
14/10/2019· The characteristics of apheresis were recorded where documented including the apheresis protocol (e.g. number of cycles), apheresis equipment (e.g., Hemonetics™ model, COBE™ Spectra™, etc.), and continuous or discontinuous removal and replacement of blood cells.
[Changes in thrombocytapheresis concentrations caused by leukocyte depletion with polyester filters]. [Article in German] Weisbach V(1), Riess H, Gindi N, Zeiler T, Riewald M, Zingsem J, Eckstein R. Author information: (1)Abteilung Innere Medizin, Universitätsklinikum Rudolf
Plateletpheresis (thrombapheresis, thrombocytapheresis) blood platelets. Plateletpheresis, like it sounds, is the collection of platelets by apheresis; while returning the RBC's, WBC's, and component plasma. The yield is normally the equivalent of between six and ten random platelet concentrates. Quality control demands the platelets from
Plasma exchange is the process of replacing the plasma removed with an equal amount of either plasma or fluid (most commonly a combination of 5% albumin and normal saline solution).. Cytapheresis is the selective removal of the cellular components of blood. Blood is withdrawn from the patient and a specific cellular component is retained (i.e., white blood cell); the remainder of other cells
Moreover, a signiﬁ- nancies, in particular in patients suﬀering from Table 8 Apheresis activity in Italy (2000): number and type of blood cell separators (BCSs) Trademark Type No. Trademark Type No. Fresenius AS104 6 Asahi Plasauto 0 Fresenius AS TEC-204 22 Baxter CS3000 24 Fresenius Plasmaﬂux 0 Baxter Autopheresis C 103 Fresenius Sulplux
View Georgia C. W.’s profile on LinkedIn, the world's largest professional community. Georgia C. has 6 jobs listed on their profile. See the complete profile on LinkedIn and discover Georgia C
Ullrich H, Kadar J, Waxenberger Y, Hohe R, Saueressig C, Heyder M, Wiebecke D. [Therapeutic thrombocytapheresis in patients with myeloproliferative diseases with the cell separators Fresenius AS 104 and Cobe Spectra: biocompatibility and safety]. Beitr
Ullrich H, Kadar J, Waxenberger Y, Hohe R, Saueressig C, Heyder M, et al. Therapeutic thrombocytapheresis in patients with myeloproliferative diseases with the cell separators Fresenius AS 104 and Cobe Spectra: Biocompatibility and safety. Beitr Infusionsther. 1992; 30:311–4.
CORPORATE PROGRAM AND EXHIBITOR GUIDE 301750 W Pender St, Vanouver, The COBE® Spectra Apheresis System and the Spectra Optia® Apheresis systems are used worldwide and consist of a variety of both therapeutic apheresis and cell collection protocols. The Spectra Optia system, introduced in 2007, is the next-generation platform that provides enhanced performance and
Transfusion Efficacy of Apheresis Platelet Concentrates Irradiated at the Day of Transfusion Is Significantly Superior Compared to Platelets Irradiated in Advance Friedgard Julmy,a Roland A. Ammann,a Stefano Fontana,c Behrouz Mansouri Taleghani,b, c
11/02/2019· One Needle Access for Peripheral Access Extracorporeal volume (ECV) can be high (bad in kids and the elderly with low total bl.vol.), fluctuations in hemodynamics Haemonetic V50 Continuous Flow Blood Withdrawn, Processed and Reinfused Simultaneously 2 venipuncture sites for peripheral access Smaller ECV, Hemodynamic Stability, faster Procedure COBE Spectra, Spectra Optia,
Drop in Hb and Hct with Fenwal CS 3000 plus and Fresenius AS-204 machines as compared with the COBE spectra were also observed by other authors. 23 CONCLUSIONS While collection of DDP contributed greatly to the PLT inventory of a transfusion service, obtaining these eligible donors from a shrinking donor population with low normal PLT values seemed to be a challenging task.
Copyright © 2022 - All Rights Reserved